Medtronic plc (MDT)
Is Medtronic Stock a Buy?
Medtronic hasn't been growing its sales at an impressive clip of late. However, one of the company's segments looks increasingly promising.
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.
Medtronic: Is The Company Back?
Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.
Diabetes and Neuro Products Ignite Medtronic's Q1 Earnings Rally
Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.
What's Next For Medtronic Stock After An Upbeat Q1?
Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics (Revised)
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
Demand for Medtronic's Medical Devices Lifts Profit and Sales
Medtronic (MDT) shares advanced in intraday trading Tuesday as the medical technology firm posted better-than-expected results and raised its guidance on strong demand for its medical devices.
Medtronic plc (MDT) Q1 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q1 2025 Earnings Conference Call August 20, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim Chief Financial Officer Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Conference Call Participants Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Travis Steed - Bank of America Securities Danielle Antalffy - UBS Securities Lawrence Biegelsen - Wells Fargo David Rescott - Baird Equity Research Matt Taylor - Jefferies David Roman - Goldman Sachs Jayson Bedford - Raymond James Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning and welcome to another Medtronic Earnings Day. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us this morning for our Fiscal 2025 First Quarter Video Earnings Webcast.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
Medtronic (MDT) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.20 per share a year ago.
Medtronic lifts profit forecast on medical devices demand, new launches
Medtronic slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches.
